The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $311.03 in the prior trading day, HCA Healthcare Inc (NYSE: HCA) closed at $297.00, down -4.51%. In other words, the price has decreased by -$4.51 from its previous closing price. On the day, 2.71 million shares were traded. HCA stock price reached its highest trading level at $304.6099 during the session, while it also had its lowest trading level at $292.97.
Ratios:
Our goal is to gain a better understanding of HCA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 76.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.76. For the most recent quarter (mrq), Quick Ratio is recorded 1.02 and its Current Ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Overweight rating and assigned the stock a target price of $356.
On January 04, 2024, Bernstein Downgraded its rating to Mkt Perform which previously was Outperform and also upped its target price recommendation from $277 to $301.
Goldman Downgraded its Buy to Neutral on December 11, 2023, while the target price for the stock was maintained at $271.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 20 ’24 when Wasserman Chad J sold 876 shares for $330.25 per share. The transaction valued at 289,299 led to the insider holds 1,576 shares of the business.
Wasserman Chad J sold 344 shares of HCA for $110,758 on Mar 18 ’24. The SVP and CIO now owns 2,452 shares after completing the transaction at $321.97 per share. On Feb 09 ’24, another insider, Whalen Kathleen M, who serves as the SVP & Chief Ethics Officer of the company, sold 4,262 shares for $306.21 each. As a result, the insider received 1,305,074 and left with 10,250 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCA now has a Market Capitalization of 78552039424 and an Enterprise Value of 122227113984. As of this moment, HCA’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.65, and their Forward P/E ratio for the next fiscal year is 12.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.21. Its current Enterprise Value per Revenue stands at 1.881 whereas that against EBITDA is 9.621.
Stock Price History:
Over the past 52 weeks, HCA has reached a high of $335.83, while it has fallen to a 52-week low of $215.96. The 50-Day Moving Average of the stock is -7.09%, while the 200-Day Moving Average is calculated to be 6.68%.
Shares Statistics:
The stock has traded on average 1.09M shares per day over the past 3-months and 1134210 shares per day over the last 10 days, according to various share statistics. A total of 265.54M shares are outstanding, with a floating share count of 191.46M. Insiders hold about 27.61% of the company’s shares, while institutions hold 65.48% stake in the company. Shares short for HCA as of 1711584000 were 2600088 with a Short Ratio of 2.39, compared to 1709164800 on 2653890. Therefore, it implies a Short% of Shares Outstanding of 2600088 and a Short% of Float of 1.34000005.
Dividends & Splits
In the trailing 12 months, HCA’s forward annual dividend rate was 2.4, compared to 2.46 this year. The stock’s 5-year Average Dividend Yield is 0.9.
Earnings Estimates
HCA Healthcare Inc (HCA) is currently under the scrutiny of HCA Healthcare, Inc. analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $23.63, with high estimates of $66.15 and low estimates of $12.99.
Analysts are recommending an EPS of between $Basic Materials and $Industrials for the fiscal current year, implying an average EPS of $Technology.
